Close Menu

Autogenomics

Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.

The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.